Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Manali Kirtikumar Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco J. Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Alexander Lunning, Victor A. Chow, Josu Santamaria, Silvia Colicino, Ken Ogasawara, Lara Stepan, Jeremy S. Abramson
Institutions: University of Colorado Cancer Center, Northside Hospital, Beth Israel Deaconess Medical Center, Mayo Clinic, Helios Hospital Berlin-Buch, University of Minnesota, OU Health Stephenson Cancer Center, Karolinska University Hospital, Karolinska Institutet, Erasmus MC, Roswell Park Comprehensive Cancer Center, National Cancer Center Hospital, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, University of Nebraska Medical Center, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Switzerland), Harvard University, Massachusetts General Hospital
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4400109280